*	OR T1 T3 T2
R1	Has_value Arg1:T5 Arg2:T6	
R2	Has_temporal Arg1:T5 Arg2:T7	
R3	Has_qualifier Arg1:T9 Arg2:T8	
R4	Has_qualifier Arg1:T9 Arg2:T11	
R5	Has_temporal Arg1:T9 Arg2:T10	
R6	Has_value Arg1:T13 Arg2:T12	
R7	Has_temporal Arg1:T13 Arg2:T14	
R8	Has_value Arg1:T16 Arg2:T17	
R9	AND Arg1:T15 Arg2:T16	
R10	Has_qualifier Arg1:T15 Arg2:T18	
R11	Has_negation Arg1:T15 Arg2:T19	
R12	Has_qualifier Arg1:T20 Arg2:T21	
R13	Has_negation Arg1:T20 Arg2:T22	
R14	Has_temporal Arg1:T24 Arg2:T26	
R15	AND Arg1:T25 Arg2:T24	
R16	Has_temporal Arg1:T20 Arg2:T23	
R17	Has_qualifier Arg1:T24 Arg2:T28	
R18	Has_negation Arg1:T24 Arg2:T27	
R19	Has_multiplier Arg1:T35 Arg2:T37	
R20	Has_temporal Arg1:T35 Arg2:T36	
R21	Has_temporal Arg1:T38 Arg2:T40	
R22	Has_multiplier Arg1:T38 Arg2:T39	
T1	Condition 21 50	Relapsing-remitting MS (RRMS)
T2	Condition 52 83	Secondary progressive MS (SPMS)
T3	Condition 88 117	Primary progressive MS (PPMS)
T4	Non-representable 146 216	Patients defined by subtype based on 2013 updated phenotypic criteria.
T5	Condition 240 251	EDSS change
T6	Value 255 274	at least 1.0 points
T7	Temporal 275 298	over the last two years
T8	Qualifier 330 341	significant
T9	Condition 342 366	change in motor function
T10	Temporal 367 389	over at least one year
T11	Qualifier 391 411	unrelated to relapse
T12	Value 414 422;430 438	55 years or older
T13	Person 426 429	age
T14	Temporal 439 463	at time of randomization
T15	Condition 492 512	inflammatory disease
T16	Measurement 539 554	Lublin criteria
T17	Value 523 531	inactive
T18	Qualifier 488 491	new
T19	Negation 466 468	No
T20	Condition 570 577	relapse
T21	Qualifier 566 569	new
T22	Negation 563 565	no
T23	Temporal 578 601	for at least five years
T24	Condition 617 623	lesion
T25	Procedure 613 616	MRI
T26	Temporal 624 648	for at least three years
T27	Negation 606 608	no
T28	Qualifier 609 612	new
T29	Drug 650 665	interferon ß-1a
T30	Drug 668 683	interferon ß-1b
T31	Drug 686 704	glatiramer acetate
T32	Drug 707 718	natalizumab
T33	Drug 721 731	fingolimod
T34	Drug 734 751	dimethyl fumarate
T35	Drug 757 770	teriflunomide
T36	Temporal 785 809	for no less than 5 years
T37	Multiplier 772 784	continuously
T38	Drug 831 834	DMT
T39	Multiplier 835 847	continuously
T40	Temporal 849 875	for no less than two years
T41	Post-eligibility 878 1058	Willing to be randomized per this protocol; each patient will be questioned as to their willingness to stay in the trial regardless of the group to which group they are randomized.
T42	Post-eligibility 1060 1090	Willing to follow the protocol
T43	Non-representable 1092 1300	Continuously will be defined as no less than 75% of all prescribed doses, with no time of greater than four weeks from last intended dose to have missed a dose (8 weeks for natalizumab, i.e. one missed dose).
